Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Milestones in Cancer Immunology

  • Milestones in Cancer Immunology
    The 2015 William B. Coley Awards
    Cancer Immunol Res December 1 2015 3 (12) 1291-1291; DOI:10.1158/2326-6066.CIR-15-0278

Cancer Immunology at the Crossroads: Biostatistics

  • Cancer Immunology at the Crossroads: Biostatistics
    Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
    Rosemarie Mick and Tai-Tsang Chen
    Cancer Immunol Res December 1 2015 3 (12) 1292-1298; DOI:10.1158/2326-6066.CIR-15-0260

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma
    Catherine Maurice, Raphael Schneider, Tim-Rasmus Kiehl, Prashant Bavi, Michael H.A. Roehrl, Warren P. Mason and David Hogg
    Cancer Immunol Res December 1 2015 3 (12) 1299-1302; DOI:10.1158/2326-6066.CIR-15-0141

    Checkpoint blockade carries risks of immune-related adverse effects, but frequency and severity are unknown. A patient is described who received anti–CTLA-4 (ipilimumab), and then anti–PD-1 (nivolumab). The patient developed lethal subacute and progressive CNS demyelination.

Priority Briefs

  • Priority Briefs
    PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
    Richard W. Joseph, Sherri Z. Millis, Estrella M. Carballido, David Bryant, Zoran Gatalica, Sandeep Reddy, Alan H. Bryce, Nicholas J. Vogelzang, Melissa L. Stanton, Erik P. Castle and Thai H. Ho
    Cancer Immunol Res December 1 2015 3 (12) 1303-1307; DOI:10.1158/2326-6066.CIR-15-0150

    Sarcomatoid renal cell cancer (RCC) is an aggressive form of RCC that responds poorly to IL2 immunotherapy. Both PD-1 and PD-L1 were found expressed in sarcomatoid RCC samples, suggesting that blockade of the PD-L1/PD-1 pathway may have immunotherapeutic potential.

  • Priority Briefs | AuthorChoice
    PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
    Kathleen M. Mahoney, Heather Sun, Xiaoyun Liao, Ping Hua, Marcella Callea, Edward A. Greenfield, F. Stephen Hodi, Arlene H. Sharpe, Sabina Signoretti, Scott J. Rodig and Gordon J. Freeman
    Cancer Immunol Res December 1 2015 3 (12) 1308-1315; DOI:10.1158/2326-6066.CIR-15-0116

    Unambiguous assessment of the presence of PD-L1 in the membrane of tumor cells could increase its utility as a prognostic marker for PD-1 blockade treatment. Three monoclonal antibodies to PD-L1's cytoplasmic domain clearly demarcated membrane from cytoplasmic staining.

Research Articles

  • Research Articles
    Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
    Arianne M. Brandsma, Toine ten Broeke, Maaike Nederend, Laura A.P.M. Meulenbroek, Geert van Tetering, Saskia Meyer, J.H. Marco Jansen, M. Alejandra Beltrán Buitrago, Sietse Q. Nagelkerke, István Németh, Ruud Ubink, Gerard Rouwendal, Stefan Lohse, Thomas Valerius, Jeanette H.W. Leusen and Peter Boross
    Cancer Immunol Res December 1 2015 3 (12) 1316-1324; DOI:10.1158/2326-6066.CIR-15-0099-T

    The efficacy of anticancer monoclonal antibodies (mAbs) is limited by the exhaustion of cellular effector mechanisms. The combination of IgG and IgA to two different tumor targets leads to enhanced cytotoxicity, providing a basis for therapeutic mAb improvements.

  • Research Articles
    Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy
    Michael J. Campa, Elizabeth B. Gottlin, Ryan T. Bushey and Edward F. Patz Jr
    Cancer Immunol Res December 1 2015 3 (12) 1325-1332; DOI:10.1158/2326-6066.CIR-15-0122

    Select early-stage lung cancer patients never develop metastasis. Some of these patients have antibodies that inactivate a protein that protects tumor cells from complement lysis, thus making tumor cells more susceptible to being killed.

  • Research Articles
    Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
    Claudia Voena, Matteo Menotti, Cristina Mastini, Filomena Di Giacomo, Dario Livio Longo, Barbara Castella, Maria Elena Boggio Merlo, Chiara Ambrogio, Qi Wang, Valerio Giacomo Minero, Teresa Poggio, Cinzia Martinengo, Lucia D'Amico, Elena Panizza, Luca Mologni, Federica Cavallo, Fiorella Altruda, Mohit Butaney, Marzia Capelletti, Giorgio Inghirami, Pasi A. Jänne and Roberto Chiarle
    Cancer Immunol Res December 1 2015 3 (12) 1333-1343; DOI:10.1158/2326-6066.CIR-15-0089

    Lung cancers harboring ALK translocations are treated with protein kinase inhibitors, which can extend survival. A cancer vaccine against ALK induced strong immune responses and enhanced survival when used alone, or in combination with kinase inhibitors or checkpoint inhibitors.

  • Research Articles | AuthorChoice
    Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
    Daniela S. Thommen, Jens Schreiner, Philipp Müller, Petra Herzig, Andreas Roller, Anton Belousov, Pablo Umana, Pavel Pisa, Christian Klein, Marina Bacac, Ozana S. Fischer, Wolfgang Moersig, Spasenija Savic Prince, Victor Levitsky, Vaios Karanikas, Didier Lardinois and Alfred Zippelius
    Cancer Immunol Res December 1 2015 3 (12) 1344-1355; DOI:10.1158/2326-6066.CIR-15-0097

    T cells within non–small cell lung cancer tumors acquire greater numbers, and more diversity, of inhibitory receptors as tumors progress, correlating with a loss in function as well as in their ability to be reactivated after anti-checkpoint treatment.

  • Research Articles
    Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma
    Yoichi Saito, Koji Ohnishi, Azusa Miyashita, Satoshi Nakahara, Yukio Fujiwara, Hasita Horlad, Takanobu Motoshima, Satoshi Fukushima, Masatoshi Jinnin, Hironobu Ihn, Motohiro Takeya and Yoshihiro Komohara
    Cancer Immunol Res December 1 2015 3 (12) 1356-1363; DOI:10.1158/2326-6066.CIR-14-0180

    Prognostic indicators are needed for malignant melanoma. The presence of high densities of CD169+ macrophages in the draining lymph nodes of patients significantly correlates with CTL infiltration and longer overall survival, providing a potentially useful biomarker.

  • Research Articles
    Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent
    C. Bryce Johnson, Brian P. Riesenberg, Bennett R. May, Stuart C. Gilreath, Guangfu Li, Kevin F. Staveley-O'Carroll, Elizabeth Garrett-Mayer, Shikhar Mehrotra, David J. Cole and Mark P. Rubinstein
    Cancer Immunol Res December 1 2015 3 (12) 1364-1374; DOI:10.1158/2326-6066.CIR-15-0087-T

    Adoptive cellular immunotherapy requires donor cells to survive and accumulate, which this study shows requires an IL12/IL7 axis in activated CD8+ T cells. IL12 leads to enhanced IL7Ra expression and IL7 responsiveness, which maximizes antitumor efficacy.

  • Research Articles
    HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
    David M. Woods, Andressa L. Sodré, Alejandro Villagra, Amod Sarnaik, Eduardo M. Sotomayor and Jeffrey Weber
    Cancer Immunol Res December 1 2015 3 (12) 1375-1385; DOI:10.1158/2326-6066.CIR-15-0077-T

    Combining other agents with immune-based approaches can enhance treatment for melanoma. PDL-1 gene expression was increased after inhibition of histone deacetylases. Combining PD-1–blockade immunotherapy with histone deacetylase inhibition increased responses in a mouse model of melanoma.

Acknowledgment to Reviewers

  • Acknowledgment to Reviewers
    Acknowledgment to Reviewers
    Cancer Immunol Res December 1 2015 3 (12) 1386-1387; DOI:10.1158/2326-6066.CIR-3-12-Reviewers

Back to top
PreviousNext
Cancer Immunology Research: 3 (12)
December 2015
Volume 3, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Milestones in Cancer Immunology
  • Cancer Immunology at the Crossroads: Biostatistics
  • Cancer Immunology Miniatures
  • Priority Briefs
  • Research Articles
  • Acknowledgment to Reviewers
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement